Skip to main content

HTRF EPIgeneous Methyltransferase kit, 1,000 Assay Points

The EPIgeneous methyltransferase assay is a kit optimized for the assessment of enzymatic methylation activity through S-adenosylhomocysteine detection (SAH).

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Part Number: 62SAHPEB
Unit Size: 1,000 Assay Points
Part Number: 62SAHPEH
Unit Size: 10,000 Assay Points
  • The EPIgeneous Methyltransferase assay is a universal solution for all methyltransferases and substrates (peptides, nucleosomes, full histones, DNA, RNA, p53 and small molecules). The detection is made via the measurement s-adenosylhomocysteine (SAH) from s-adenosylmethinionine (SAM) conversion by methyltransferases. The assay is compatible with most enzyme with a Km for SAM between 0.4 µM 200 µM. The assay provides a unique and robust alternative to radioactivity.

  • Assay Points
    Assay Target Type
    Assay Technology
    Therapeutic Area
    Oncology & Inflammation
    Unit Size
    1,000 Assay Points
  • Enzymatic step principle

    The EPIgeneous™ Methyltransferase Assay is a universal biochemical assay for all enzymes within the histone (HMTs) and DNA (DNMTs) methyltransferase families that produce S-adenosylhomocysteine (SAH). The methyltransferase activity is assessed by measuring the conversion of SAM (S-5’adenosyl-L-methionine) to SAH.



    Detection step principle

    In order to directly measure SAH release, an anti SAH antibody labeled with Tb cryptate and a SAH-d2 tracer are used. The SAH released by the enzymatic reaction competes with the SAH-d2 labeled leading a decrease of the HTRF signal.



    Assay protocol

    The substrate is incubated with the enzyme in presence of compounds. SAM (CH3 donor) is added to start the enzymatic reaction leading to the substrate methylation. The antibody specific to SAH labeled with Tb cryptate competes with both native SAH and d2-coupled SAH. The resulting TR-FRET signal is inversely proportional to the concentration of SAH in the calibrator or in the sample.



  • DOT1L Enzyme titration

    Human recombinant DOT1L was serially diluted in enzymatic buffer from 320 nM to 0.001 nM. The assay carried out with 10 ng/µl (= 77 nM) oligonucleosome as substrate and 2 µM SAM for 2 h at 30°C. The negative controls (no SAM or no nucleosome) confirm the measurement the enzymatic specific activity. A DOT1L concentration of 4.5 nM (EC80) was selected for further experiments. This concentration leads to 10% conversion of SAM into SAH.



    Inhibition effect of SGC0946 on DOT1L assay

    The EPIgeneous methyltransferase assay was performed using 0.5 µM SAM (EC40), 77 nM oligonucleosome (EC80) and 4.5 nM DOT1L (EC80). The enzymatic reaction was stopped with the detection reagents after 2h incubation at 30°C. IC50 of SGC0946 is in good agreement with the literature (Yu et al. Nature commun., 2012). As expected, BIX01294, a G9a selective inhibitor, does not inhibit DOT1L. Controls of inhibitors without enzyme show that they do not affect the detection reagents.



    Assay sensitivity

    The graph represents the assay windows obtained with a range of SAM concentrations and at different conversion percentages of SAM into SAH. The assay was performed using the calibration curve of the kit prepared with the assay diluent The EPIgeneous methyltransferase assay has been optimized to be suitable for a large range of SAM concentrations in the enzymatic step (0.4 – 200 µM). With these concentrations of SAM, the assay is able to assess the enzymatic activity with 4 to 10% turnover of the enzyme (hence 4 to 10% conversion of SAM into SAH).




1-1 of 1 Resources
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.